John A. Orwin
John A. Orwin joined the Seattle Genetics Board of Directors in January 2014. Since June 2013, he has served as Chief Executive Officer and member of the Board of Relypsa, a clinical-stage pharmaceutical company. Prior to Relypsa, he was at Affymax, serving most recently as Chief Executive Officer and a member of the Board of Directors. Previously, Mr. Orwin was Vice President and then Senior Vice President of the BioOncology Business Unit at Genentech (now a member of the Roche Group), where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech's oncology portfolio in the United States. He has also held senior marketing and sales positions at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation.
Mr. Orwin received an M.B.A. from New York University and a B.A. from Rutgers University. He also serves on the Boards of Directors of Array BioPharma and Retrophin, Inc.